Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Ranibizumab
Related studies linked through entity extraction aliases.
Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO
- Status
- UNKNOWN
- Phase
- NA
Analysis of Aqueous and Vitreous Humor
- Status
- UNKNOWN
- Phase
- PHASE2
Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration
- Status
- COMPLETED
- Phase
- PHASE4
Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema
- Status
- UNKNOWN
- Phase
- PHASE4
Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema
- Status
- WITHDRAWN
- Phase
- PHASE4
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration
- Status
- WITHDRAWN
- Phase
- PHASE3
A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
- Status
- COMPLETED
- Phase
- PHASE3
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
- Status
- TERMINATED
- Phase
- PHASE2
Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye
- Status
- COMPLETED
- Phase
- PHASE4
Safety and Efficacy of Ranibizumab for Diabetic Macular Edema
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)
- Status
- COMPLETED
- Phase
- PHASE4
Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia
- Status
- COMPLETED
- Phase
- PHASE1
Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD
- Status
- COMPLETED
- Phase
- PHASE4
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
- Status
- TERMINATED
- Phase
- PHASE3
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
- Status
- TERMINATED
- Phase
- PHASE3
Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration
- Status
- COMPLETED
- Phase
- N/A